Lomitapide Mesylate

甲磺酸洛美他派

Report date: 2026/03/19 20:00:18
NMEFirst In Class

Base Information

Drug NameLomitapide Mesylate
Drug Alias NameLomitapide Mesilate洛美他派罗米他匹lomitapidalomitapide +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMicrosomal triglyceride transfer protein inhibitors
TargetsMicrosomal triglyceride transfer protein
Therapy Area/IndicationsHomozygous familial hypercholesterolemiaHypercholesterolemiaHyperlipidemias +[4] 
Global Approved IndicationsHomozygous familial hypercholesterolemia
Approved Indications in ChinaHomozygous familial hypercholesterolemia
Original Approved Country/TerritoryUnited States
Original Approved Date2012/12/21
Country/TerritoryCanadaUnited StatesSouth Africa +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAegerion Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesMedison PharmaChiesi Global Rare DiseasesAmryt Pharmaceuticals Dac +[5] 
Inactive CompaniesN/A
Active IndicationsHomozygous familial hypercholesterolemia
Inactive IndicationsHypercholesterolemiaHyperlipidemiasHyperlipoproteinemia Type II

Other Information

ATC CodeC10AX12
Related LinksWikipediaDrugBankKEGG